Clinical Trial Update: Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma [NA]

View source ↗

Summary

Clinical trial update describing a study of bortezomib and filgrastim to promote stem cell mobilization in patients with various B-cell non-Hodgkin lymphomas an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Filgrastim (filgrastim)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | NA | Status: COMPLETED | Results posted: 2021-05-10